Medically reviewed by Gagandeep Brar, MD Stage 1 and 2 prostate cancer stays in your prostate, and the five-year survival ...

Prostate cancer is one of the most commonly diagnosed cancers in men, but Wisconsin’s survival rate trails much of the nation ...

Mortality from cancer for those aged 75 years or younger is now 11 per cent lower than the European Union average. For a ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime The average age at diagnosis is 67 Less than 1% of the 3.5 million men living with prostate cancer are expected to die from it ...

Men diagnosed with nonmetastatic prostate cancer can generally expect to live for many years after their diagnosis. However, ...

Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery or radiation.

Opevesostat (Merck). A first-in-class CYP11A1 inhibitor that shuts down androgen production at its source, opevesostat is in two phase 3 trials, OMAHA-003 and OMAHA-004, for metastatic ...

Investigators evaluated progression-free survival in men with high-risk prostate cancer assigned to dose-escalated ...

Prostate cancer screening does not necessarily need to be performed every year. “If your PSA levels are very low, your ...

Harvard scientists have pinpointed the dietary changes that may lower the risk of death following a cancer diagnosis and ...

Tumor DNA profiling could be used to identify which men with metastatic prostate cancer need aggressive treatment and those who may benefit from de-escalation.A model, trained and tested on nearly ...